1,828
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma

, , , , , & show all
Pages 219-227 | Received 09 Aug 2018, Accepted 04 Dec 2018, Published online: 21 Jan 2019
 

Abstract

Objective: To determine the safety and efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma.

Material and methods: We conducted an observational study in 156 patients with advanced renal cell carcinoma unsuitable for surgical treatment. Participants received cryoablation + sorafenib (n = 67) or sorafenib only (n = 89). Objective response rate (ORR), disease control rate (DCR), progression-free survival time (PFS), overall survival (OS), change in immune function after treatment, rate of adverse events, and quality of life were compared between the two groups.

Results: In the cryoablation + sorafenib group, ORR and DCR were significantly higher and PFS and OS were significantly longer than in the sorafenib only group (both p < .05). Immune function-related indicators were significantly improved after treatment in the cryoablation + sorafenib group (p < .05), but no significant difference was found between before and after treatment in the sorafenib only group (p > .05). The incidence of targeted drug-related side effects was not significantly different between the groups (p > .05), and cryoablation did not increase the risk of side effects of targeted drugs.

Conclusion: Cryoablation combined with sorafenib had superior clinical efficacy compared with sorafenib-only for the treatment of advanced renal cell carcinoma unsuitable for surgical treatment. Moreover, this combined therapy may enhance the body’s anti-tumor immunity and effectively prolong PFS and OS without compromising patient quality of life, thus representing a new treatment strategy for advanced renal cell carcinoma.

Disclosure statement

The authors report no conflicts of interest.

Additional information

Funding

This study was funded by National Natural Science Foundation of China [81471761, 81501568]; National five-year science and technology support plan [No. 2012BAI15 B06]; Tianjin Program for Anticancer Major Projects [12ZCDZSY20300]; Tianjin science and technology support plan key projects [15ZCZDSY00890].